X-Linked Hypophosphatemia (XLH) Life Course Analysis: A Retrospective Cross-Sectional Study

Study identification

• EU PAS number:
  EUPAS32590
• Study ID:
  44131
• Official title and acronym:
  X-Linked Hypophosphatemia (XLH) Life Course Analysis: A Retrospective Cross-Sectional Study
• DARWIN EU® study:
  No
• Study countries:
  United Arab Emirates
• Study description:
  The objective of this study is to undertake a life course analysis of X-Linked Hyophosphatemia (XLH) in adulthood (from 18 years old onwards) in order to gain an understanding of adult disease manifestations, reported healthcare resource use and patient reported quality over the XLH life course.
• Study status:
  Finalised

Research institutions and networks

Institutions

Kyowa Kirin

Study timelines

Date when funding contract was signed

Planned:03/06/2019

Actual:02/09/2019

Study start date

Planned:01/10/2019

Actual:07/10/2019

Date of final study report

Planned:01/12/2020

Actual:01/11/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Kyowa Kirin

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable